The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OSUR | -29.83% | -80.75% | -28.07% | -30% |
| S&P | +14.5% | +93.32% | +14.09% | +1,859% |
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.
Investors applauded the diagnostics company's Q4 update.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $31.24M | -42.5% |
| Gross Profit | $11.69M | -54.3% |
| Gross Margin | 37.42% | -9.7% |
| Market Cap | $224.40M | -28.8% |
| Market Cap / Employee | $0.45M | 0.0% |
| Employees | 501 | -21.5% |
| Net Income | -$19.69M | -3102.1% |
| EBITDA | -$14.77M | -674.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $234.58M | -9.2% |
| Accounts Receivable | $25.90M | -32.0% |
| Inventory | 33.4 | -12.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $11.98M | 14.1% |
| Short Term Debt | $2.15M | 1.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -11.20% | -17.1% |
| Return On Invested Capital | -1.33% | -2.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$12.16M | -295.3% |
| Operating Free Cash Flow | -$10.22M | -230.3% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 11.38 | 20.24 | 11.80 | 28.39 | - |
| Price to Book | 0.75 | 0.63 | 0.61 | 0.57 | -23.08% |
| Price to Sales | 1.42 | 1.45 | 1.56 | 1.61 | 39.77% |
| Price to Tangible Book Value | 0.82 | 0.69 | 0.71 | 0.67 | -17.58% |
| Price to Free Cash Flow TTM | 3.38 | 3.66 | 4.98 | 11.42 | 143.77% |
| Enterprise Value to EBITDA | -19.64 | -1.41 | -1.23 | -0.21 | -100.90% |
| Free Cash Flow Yield | 29.6% | 27.3% | 20.1% | 8.8% | -58.98% |
| Return on Equity | 2.7% | -4.6% | -7.8% | -12.7% | -291.92% |
| Total Debt | $11.11M | $14.60M | $14.20M | $14.13M | 11.89% |
OSUR earnings call for the period ending September 30, 2021.
OSUR earnings call for the period ending June 30, 2021.
OSUR earnings call for the period ending March 31, 2021.
OSUR earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
